Starboard Acquires Becton Dickinson
This is a news story, published by CNBC, that relates primarily to Becton Dickinson news.
Becton Dickinson news
For more Becton Dickinson news, you can click here:
more Becton Dickinson newsemerging technologies news
For more emerging technologies news, you can click here:
more emerging technologies newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best tech news, business news, entertainment news, and much more. If you like emerging technologies news, you might also like this article about
Becton Dickinson. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other shareholders news, global medical technology company news, emerging technologies news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
MedTech businessCNBC
•Technology
Technology
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit

78% Informative
Becton Dickinson ( BDX ) is a global medical technology company comprised of essentially two businesses.
The company operates two distinct businesses that are at different stages with different growth rates and valuation multiples.
If separated, the Medtech Business should get a 13 -times to 14 -times EBITDA valuation based on its growth, while Life Sciences should receive a valuation north of 20 -times.
If separated, the Medtech Business should get a 13 -times to 14 -times EBITDA valuation based on its growth.
Life Sciences could get a valuation north of 20 -times at the low end of the multiple range.
The real value comes from two separate management teams being able to better focus on and devote resources to their own businesses.
VR Score
78
Informative language
77
Neutral language
46
Article tone
semi-formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
1
Source diversity
1
Affiliate links
no affiliate links